References
- Mostoufi-Moab S, Seidel K, Leisenring WM, et al. Endocrine abnormalities in aging survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2016;34(27):3240–3247.
- Persani L. Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97(9):3068–3078.
- Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, et al. Hypopituitarism. Lancet. 2007;369(9571):1461–1470.
- Chemaitilly W, Sklar CA. Childhood cancer treatments and associated endocrine late effects: a concise guide for the pediatric endocrinologist. Horm Res Paediatr. 2019;91(2):74–82.
- Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer. 2010;17(3):R141–59.
- Persani L, Brabant G, Dattani M, et al. European thyroid association (ETA) guidelines on the diagnosis and management of Central hypothyroidism. Eur Thyroid J. 2018;7(5):225–237.
- Baronio F, Battisti L, Radetti G. Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia. J Pediatric Endocrinol Metab JPEM. 2011;24(11–12):903–906.
- Izaki S, Goto H, Okuda K, et al. Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. Int J Hematol. 2007;86(3):253–260.
- Yeung SC, Chiu AC, Vassilopoulou-Sellin R, et al. The endocrine effects of nonhormonal antineoplastic therapy. Endocrine Reviews. 1998;19(2):144–172.
- Armstrong AE, Danner-Koptik K, Golden S, et al. Late effects in pediatric high-risk neuroblastoma survivors after intensive induction chemotherapy followed by myeloablative consolidation chemotherapy and triple autologous stem cell transplants. J Pediatric Hematol Oncol. 2018;40(1):31–35.
- Ansari S, Rostami T, Kiumarsi A. Central hypothyroidism: a rare complication in a child undergoing chemotherapy for acute lymphoblastic leukaemia. Iranian J Blood Cancer. 2014;7(1):49–52.
- Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden Central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999;84(12):4472–4479.
- Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatric Endocrinol Metab JPEM. 2004;17(1):55–66.
- Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-Pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(8):2761–2784.
- Gebauer J, Higham C, Langer T, et al. Long-Term endocrine and metabolic consequences of cancer treatment: a systematic review. Endocr Rev. 2019;40(3):711–767.
- van Iersel L, Li Z, Srivastava DK, et al. Hypothalamic-Pituitary disorders in childhood cancer survivors: prevalence, risk factors and long-term health outcomes. J Clin Endocrinol Metab. 2019;104(12):6101–6115.
- Seejore K, Kyriakakis N, Murray RD. Is chemotherapy implicated in the development of hypopituitarism in childhood cancer survivors? J Clin Endocrinol Metab. 2020;105(4):61.
- Zhang Y-X, Shen C-H, Lai Q-L, et al. Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: a meta-analysis. Seizure. 2016;35:72–79.
- Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol. 2015;8(6):741–750.
- Yılmaz Ü, Yılmaz TS, Akıncı G, et al. The effect of antiepileptic drugs on thyroid function in children. Seizure. 2014;23(1):29–35.
- Miller J, Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatr Neurol. 2006;34(3):242–244.